Clinical, histological, immunophenotypic, and molecular cytogenetic features of pediatric ALK-positive DLBCL showed expression of the immunoglobulin light chain lambda, whereas the other two cases expressed the kappa light chain. With regard to the ALK protein, its expression was restricted to the cytoplasm that showed a fine granular pattern in all three cases (Supplementary Figure 1) . This pattern is typical for ALK-CLTC fusions, because the clathrin gene encodes for a coated vesicle protein involved in intracellular transport. Thus, we performed fluorescence in situ hybridization (FISH) on paraffinembedded tissue sections with probes specific for the ALK (LSI ALK, Vysis/Abbott, Downers Grove, USA) and CLTC (BAC clones RP11-316J18 and CTD-2601E3) loci. FISH was carried out as previously described. 1 All three cases showed a split of the dual-color probe flanking ALK, indicating a chromosomal break within the ALK gene (Supplementary Figure 1) . In order to confirm the presence of an ALK-CLTC fusion, a three-color interphase FISH assay was applied combining the ALK probe labeled in Spectrum Green and Spectrum Orange with the CLTC BACs labeled in Texas Red. Owing to limited hybridization efficiency, only case 1 could be evaluated, and a dissociation of the probe for the CLTC locus into two small signals was seen (pink signals, Supplementary Figure 1) . One part of the CLTC probe is co-localized to the centromeric ALK probe (green), and the other part to the telomeric ALK probe (red), confirming the reciprocal translocation t(2;17)(p23;q23).
In cases 2 and 3, a CLTC dual-color break-apart probe was applied containing the BAC clones flanking the CLTC locus labeled in Spectrum Green and Spectrum Orange. In case 2, a dissociation of orange and green signals was detected, which confirmed the breakpoint in the CLTC gene, and strongly suggests the presence of an ALK-CLTC fusion. In case 3, the CLTC dual-color break-apart probe was not evaluable. However, the breakpoint in the ALK locus detected by FISH and the characteristic granular cytoplasmic ALK expression pattern also suggest the presence of an ALK-CLTC fusion in case 3.
Interestingly, ALK-CLTC fusions are rarely observed as variant translocations in anaplastic large cell lymphoma and inflammatory myofibroblastic tumor, 6 but seem to be the genetic hallmarks of B-cell lymphomas expressing the ALK protein.
The findings described in this report show that ALK-CLTC fusions are not restricted to adult forms of ALK-positive DLBCL, but are also recurrent in ALK-positive DLBCL arising in children.
Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy The patient, a 51-old-year male, working as orthopaedic technician, at the onset of disease (November 1998) reported no risk factors regarding liver diseases or viral infections. His clinical features through the disease course are reported in Table 1 . He presented stable disease until November 2001, when fludarabine was started because of progressive disease, after a comprehensive assessment including serum HBsAg and HBeAg, antibodies against the B-core antigen (HBcAb), HBe (HBeAB), HBsAg (HBsAb), HCV, hepatitis A and delta virus, cytomegalovirus, and Epstein-Barr virus. HBcAb were positive, while HBsAb and all other markers were negative. A good partial response (GPR) was obtained so that the patient received four weekly standard doses (375 mg/m 2 ) of rituximab as consolidation therapy (July 2002), achieving a complete remission (CR). The patient was then closely
